Screening of prostate cancer is performed globally by digital rectal examination (DRE), the prostate-specific antigen (PSA) blood test, and transrectal ultrasound (TRUS)-guided biopsy [2]. This evidence concerns the gene KLK3 and prostate carcinoma.